The bulk drugs segment of the Indian pharmaceutical sector is expected to see revenue grow at 6-8 per cent this fiscal year, helped by higher sales volume stemming from a stable growth outlook, according to a Crisil Ratings report.
Mumbai (Maharashtra) [India], Aug 10 (ANI): The Indian government's recent incentives to boost domestic manufacturing of active pharmaceutical ingredients (APIs) and key starting materials (KSMs) can improve backward integration over the next few years and curtail supply-chain disruption ris